Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer

被引:75
作者
Chong, Curtis R. [1 ]
Bahcall, Magda [1 ]
Capelletti, Marzia [1 ]
Kosaka, Takayuki [1 ]
Ercan, Dalia [1 ]
Sim, Taebo [2 ,3 ]
Sholl, Lynette M. [4 ]
Nishino, Mizuki [5 ,6 ]
Johnson, Bruce E. [1 ]
Gray, Nathanael S. [7 ,8 ]
Janne, Pasi A. [1 ,9 ]
机构
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, 450 Brookline Ave,LC4114, Boston, MA 02215 USA
[2] Korea Inst Sci & Technol, Chem Kinom Res Ctr, Seoul, South Korea
[3] KU KIST Grad Sch Converging Sci & Technol, Seoul, South Korea
[4] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA USA
[8] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA
[9] Dana Farber Canc Inst, Belfer Ctr Appl Canc Sci, Boston, MA 02115 USA
关键词
CRIZOTINIB RESISTANCE; CABOZANTINIB; INHIBITOR; ONCOGENE;
D O I
10.1158/1078-0432.CCR-15-1601
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Efforts to discover drugs that overcome resistance to targeted therapies in patients with rare oncogenic alterations, such as NTRK1 and ROS1 rearrangements, are complicated by the cost and protracted timeline of drug discovery. Experimental Design: In an effort to identify inhibitors of NTRK1 and ROS1, which are aberrantly activated in some patients with non-small cell lung cancer (NSCLC), we created and screened a library of existing targeted drugs against Ba/F3 cells transformed with these oncogenes. Results: This screen identified the FDA-approved drug cabozantinib as a potent inhibitor of CD74-ROS1-transformed Ba/F3, including the crizotinib-resistant mutants G2032R and L2026M (IC50 = 9, 26, and 11 nmol/L, respectively). Cabozantinib inhibited CD74-ROS1-transformed Ba/F3 cells more potently than brigatinib (wild-type/G2032R/L2026M IC50 = 30/170/200 nmol/L, respectively), entrectinib (IC50 = 6/2,200/3,500 nmol/L), and PF-06463922 (IC50 = 1/270/2 nmol/L). Cabozantinib inhibited ROS1 autophosphorylation and downstream ERK activation in transformed Ba/F3 cells and in patient-derived tumor cell lines. The IGF-1R inhibitor BMS-536924 potently inhibited CD74-NTRK1-transformed compared with parental Ba/F3 cells (IC50 = 19 nmol/L vs. > 470 nmol/L). A patient with metastatic ROS1-rearranged NSCLC with progression on crizotinib was treated with cabozantinib and experienced a partial response. Conclusions: While acquired resistance to targeted therapies is challenging, this study highlights that existing agents may be repurposed to overcome drug resistance and identifies cabozantinib as a promising treatment of ROS1-rearranged NSCLC after progression on crizotinib. (C) 2016 AACR.
引用
收藏
页码:204 / 213
页数:10
相关论文
共 31 条
[21]   Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer [J].
Shaw, Alice T. ;
Ou, Sai-Hong I. ;
Bang, Yung-Jue ;
Camidge, D. Ross ;
Solomon, Benjamin J. ;
Salgia, Ravi ;
Riely, Gregory J. ;
Varella-Garcia, Marileila ;
Shapiro, Geoffrey I. ;
Costa, Daniel B. ;
Doebele, Robert C. ;
Long Phi Le ;
Zheng, Zongli ;
Tan, Weiwei ;
Stephenson, Patricia ;
Shreeve, S. Martin ;
Tye, Lesley M. ;
Christensen, James G. ;
Wilner, Keith D. ;
Clark, Jeffrey W. ;
Iafrate, A. John .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (21) :1963-1971
[22]  
Shen L, 2014, NEW ENGL J MED, V370, P2537, DOI [10.1056/NEJMoa1311107, 10.1056/NEJMc1404894]
[23]   Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study [J].
Smith, Matthew R. ;
Sweeney, Christopher J. ;
Corn, Paul G. ;
Rathkopf, Dana E. ;
Smith, David C. ;
Hussain, Maha ;
George, Daniel J. ;
Higano, Celestia S. ;
Harzstark, Andrea L. ;
Sartor, A. Oliver ;
Vogelzang, Nicholas J. ;
Gordon, Michael S. ;
de Bono, Johann S. ;
Haas, Naomi B. ;
Logothetis, Christopher J. ;
Elfiky, Aymen ;
Scheffold, Christian ;
Laird, A. Douglas ;
Schimmoller, Frauke ;
Basch, Ethan M. ;
Scher, Howard I. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (30) :3391-U224
[24]   Enzymatic Characterization of c-Met Receptor Tyrosine Kinase Oncogenic Mutants and Kinetic Studies with Aminopyridine and Triazolopyrazine Inhibitors [J].
Timofeevski, Sergei L. ;
McTigue, Michele A. ;
Ryan, Kevin ;
Cui, Jean ;
Zou, Helen Y. ;
Zhu, Jeff X. ;
Chau, Fannie ;
Alton, Gordon ;
Karlicek, Shannon ;
Christensen, James G. ;
Murray, Brion W. .
BIOCHEMISTRY, 2009, 48 (23) :5339-5349
[25]   TRKing Down an Old Oncogene in a New Era of Targeted Therapy [J].
Vaishnavi, Aria ;
Le, Anh T. ;
Doebele, Robert C. .
CANCER DISCOVERY, 2015, 5 (01) :25-34
[26]   Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer [J].
Vaishnavi, Aria ;
Capelletti, Marzia ;
Le, Anh T. ;
Kako, Severine ;
Butaney, Mohit ;
Ercan, Dalia ;
Mahale, Sakshi ;
Davies, Kurtis D. ;
Aisner, Dara L. ;
Pilling, Amanda B. ;
Berge, Eamon M. ;
Kim, Jhingook ;
Sasaki, Hidefumi ;
Park, Seung-il ;
Kryukov, Gregory ;
Garraway, Levi A. ;
Hammerman, Peter S. ;
Haas, Julia ;
Andrews, Steven W. ;
Lipson, Doron ;
Stephens, Philip J. ;
Miller, Vince A. ;
Varella-Garcia, Marileila ;
Jaenne, Pasi A. ;
Doebele, Robert C. .
NATURE MEDICINE, 2013, 19 (11) :1469-+
[27]   High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing [J].
Wagle, Nikhil ;
Berger, Michael F. ;
Davis, Matthew J. ;
Blumenstiel, Brendan ;
DeFelice, Matthew ;
Pochanard, Panisa ;
Ducar, Matthew ;
Van Hummelen, Paul ;
MacConaill, Laura E. ;
Hahn, William C. ;
Meyerson, Matthew ;
Gabriel, Stacey B. ;
Garraway, Levi A. .
CANCER DISCOVERY, 2012, 2 (01) :82-93
[28]   Ba/F3 cells and their use in kinase drug discovery [J].
Warmuth, Markus ;
Kim, Sungjoon ;
Gu, Xiang-ju ;
Xia, Gang ;
Adrian, Francisco .
CURRENT OPINION IN ONCOLOGY, 2007, 19 (01) :55-60
[29]   Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells [J].
Weisberg, Ellen ;
Liu, Qingsong ;
Zhang, Xin ;
Nelson, Erik ;
Sattler, Martin ;
Liu, Feiyang ;
Nicolais, Maria ;
Zhang, Jianming ;
Mitsiades, Constantine ;
Smith, Robert W. ;
Stone, Richard ;
Galinsky, Ilene ;
Nonami, Atsushi ;
Griffin, James D. ;
Gray, Nathanael .
PLOS ONE, 2013, 8 (02)
[30]   The human 18S U11/U12 snRNP contains a set of novel proteins not found in the U2-dependent spliceosome [J].
Will, CL ;
Schneider, C ;
Hossbach, M ;
Urlaub, H ;
Rauhut, R ;
Elbashir, S ;
Tuschl, T ;
Lührmann, R .
RNA, 2004, 10 (06) :929-941